Screener
AngioDynamics ANGO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: AngioDynamics’s 10-Q, filed April 2, 2026.
- Filed
- Apr 2, 2026, 12:00 AM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-023008
| Line item | Nine Months Ended / Feb 28, 2026 | Nine Months Ended / Feb 28, 2025 |
|---|---|---|
| Proceeds from financing arrangement | — | 6,310 |
| Repurchase of common stock | — | (1,670) |
| Proceeds from exercise of stock options and employee stock purchase plan | 950 | 933 |
| Net cash provided by financing activities | 672 | 5,515 |
| Effect of exchange rate changes on cash | 287 | (317) |
| Decrease in cash | (18,083) | (31,296) |
| Cash at beginning of period | 55,893 | 76,056 |
| Cash at end of period | $37,810 | $44,760 |
Item 1. Financial Statements.
FAQ
- What is AngioDynamics's financing cash flow?
- AngioDynamics (ANGO) reported financing cash flow of $621K in Q4 2025.
- How has AngioDynamics's financing cash flow changed year-over-year?
- AngioDynamics's financing cash flow decreased by 91.3% year-over-year, from $7.15M to $621K.
- What is the long-term trend for AngioDynamics's financing cash flow?
- Over 3 years (2022 to 2025), AngioDynamics's financing cash flow has grown at a -67.9% compound annual growth rate (CAGR), from $7.68M to -$255K.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about AngioDynamics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude